Catalyst4, Inc., an insider at MapLight Therapeutics, Inc. (MLPT), disclosed a fresh open-market purchase in a Form 4 filing with the SEC. The transaction, dated August 14, 2026, shows Catalyst4 buying 4,400,000 shares at $11.38 apiece, a total outlay of $50,072,000.00 paid with the insider’s own funds.
Following the purchase, Catalyst4 reports beneficial ownership of 25,306,689 shares, held indirectly through an entity structure rather than in the insider’s own name. That indirect holding format is common for institutional or affiliated insiders who route positions through trusts or investment vehicles, and it does not change how the transaction is classified for disclosure purposes.
A Continuation of Recent Buying
This is not the first time Catalyst4 has stepped into the open market for MLPT shares. Just weeks earlier, the same insider purchased roughly $13 million worth of stock as part of a broader cluster of insider buying at the company that topped $15.3 million in total. Readers can find more detail on that earlier activity in our prior coverage: MLPT Insider Catalyst4 Buys $13M as Cluster Buy Tops $15.3M.
Taken together, the two disclosures show Catalyst4 committing well over $60 million to MLPT shares in a span of roughly two weeks, a pace that stands out even among insider filings that already track meaningfully large positions.
Why Clustered Buying Draws Attention
Academic research on insider trading patterns has found that clustered purchases, meaning multiple buys from the same insider or several insiders within a short window, tend to correlate statistically with subsequent stock outperformance more often than isolated single purchases. This filing fits that clustered pattern, following directly on the heels of the late-July transaction.
None of this changes the nature of the disclosure itself: it is a factual record of an insider using personal or entity funds to acquire shares on the open market, filed as required under securities law. The size of the purchase, combined with the recency of the prior buy, is likely to keep MLPT on the radar of investors who track insider activity as one data point among many when evaluating a company.
Further Form 4 filings from Catalyst4 or other MapLight Therapeutics insiders, if any follow, would provide additional context on whether this buying pattern continues.
→ See all MLPT coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.